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Abstract
For patients with inoperable liver metastases, intra-operative liver high dose-rate brachytherapy (HDR-BT) is a promising
technology enabling delivery of a high radiation dose to the tumor, while sparing healthy tissue. Liver brachytherapy has
been described in the literature as safe and effective for the treatment of primary or secondary hepatic malignancies. It is
preferred over other ablative techniques for lesions that are either larger than 4cm or located in close proximity to large
vessels or the common bile duct. In contrast to external beam radiation techniques, organ movements do not affect the
size of the irradiated volume in intra-operative HDR-BT and new technical solutions exist to support image guidance for
intra-operative HDR-BT. We have retrospectively analyzed anonymized CT datasets of 5 patients who underwent open
liver surgery (resection and/or ablation) in order to test whether the accuracy of a new image-guidance method specifically
adapted for intra-operative HDR-BT is high enough to use it in similar situations and whether patients could potentially
benefit from navigation-guided intra-operative needle placement for liver HDR-BT.
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Genauigkeitsabschätzung einer möglichen klinischen Anwendung der navigationsgestützten
intraoperativen Lebermetastasen-Brachytherapie – Eine Planungsstudie
Zusammenfassung
Für Patienten mit inoperablen Lebermetastasen ist die intraoperative Hochdosis-Brachytherapie (HDR-BT) eine vielver-
sprechende Technologie, die es ermöglicht, eine hohe Strahlendosis auf den Tumor zu liefern, während das umliegende
gesunde Gewebe geschont wird. Die Leber-BT wurde in der Literatur als sicher und wirksam für die Behandlung von
primären oder sekundären Tumoren in der Leber beschrieben. Sie ist für Läsionen mit einer Größe > 4cm oder in un-
mittelbarer Nähe zu großen Gefäßen sowie in engem Kontakt mit dem zentralen Gallengang gegenüber anderen ablativen
Verfahren zu bevorzugen. Im Gegensatz zu den externen Strahlentherapietechniken wirken sich bei der intraoperativen
HDR-BT Organbewegungen nicht auf die Größe des bestrahlten Volumens aus. Neue bildgestützte technische Lösungen
existieren, um die intraoperative Applikatoreinlage für die HDR-BT zu unterstützen. Wir haben retrospektiv anonymisierte
Computertomographiedatensätze von 5 Patienten analysiert, welche eine offene Leberoperation erhalten haben (Resekti-
on und/oder Ablation). Hierbei testeten wir, ob die Genauigkeit der speziell für die intraoperative HDR-BT angepasste
Navigation ausreicht, um sie in vergleichbaren Situationen anzuwenden, und ob Patienten möglicherweise von der neuen
Bildführungsmethode zur intraoperativen Nadelplatzierung bei der Leber-HDR-BT profitieren könnten.
Schlüsselwörter Leber · Brachytherapie · Bildführung · Radiotherapie · Lebermetastasen
Introduction
Colorectal cancer (CRC) is the most frequent primary site to
give rise to metastatic liver disease. The role of local ther-
apy has been most thoroughly evaluated in CRC hepatic
metastases [1]. Surgical resection has become the preferred
treatment for these patients, since it can provide cure of
disease and is associated with 5-year survival rates in the
range of 25–47% [2–5]. However, due to associated co-
morbidities, non-resectable extrahepatic disease, or multi-
ple liver lesions with inadequate residual functioning liver
parenchyma after surgery, 70–80% of patients with colorec-
tal liver metastases are not candidates for resection [6]. This
has encouraged the use of alternative surgical approaches,
such as radiofrequency and microwave tumor ablation, as
well as cryotherapy and other ablative techniques [7]. For
small tumors, radiofrequency ablation (RF) or microwave
ablation (MWA) achieve excellent local control [8]. How-
ever, high local recurrence rates of up to 39% [9], particu-
larly in tumors> 3cm and tumors adjacent to large vessels
[8, 10], remain a challenge. There is growing interest in ap-
plying radiotherapy to hepatic malignancies. A decade ago,
image-guided high dose-rate brachytherapy (HDR-BT) of
liver tumors was introduced [11] as a local radio-ablative
technique, in which an iridium-192 source is temporarily
inserted into the tumor through catheters placed under im-
age guidance [12]. HDR-BT is preferred over other ther-
mal ablative techniques for lesions> 4cm in size or located
near large vessels as well as those in close contact with the
central bile duct [13, 14, 33, 34]. Any HDR-BT interven-
tion within the liver requires an in-depth three-dimensional
(3D) understanding of the organ’s internal vascular and bil-
iary anatomy. To optimize the treatment outcomes, it is
important that these procedures result in accurate position-
ing of the needle to achieve complete tumor dose cover-
age and minimize the probability of damage to surround-
ing normal tissue. Moreover, there might be organs at risk
(OAR)—such as the hepatic arteries, portal veins, and bile
ducts—in the proximity of the needle path that imperatively
should not be touched. For surgical interventions, the intro-
duction of pre-operative 3D imaging data from computer
tomography (CT) or magnetic resonance imaging (MRI)
in the early 1990s enabled surgeons to virtually plan and
evaluate surgical strategies prior to the actual surgery us-
ing the available imaging data [36]. Clinically applicable
surgical planning solutions are nowadays available [37].
Computer-assisted open liver surgery has now been avail-
able for 10 years, but only recently were image guidance
systems specifically optimized for hepatopancreaticobiliary
(HPB) surgery [15, 38]. The missing link between virtual
surgery planning and pre-operative evaluation is intra-op-
erative navigation support for the real-time reproduction of
the virtually planned surgical intervention, with the goal of
increased precision of the planned intervention. Such a nav-
igation support consisting of an optically based instrument
guidance system is already in use in our hospital for open
liver surgery [15] and MWA [16], and may also facilitate
the intra-operative and CT-guided application of HDR-BT.
The aim of the current study is twofold: to translate the
knowledge from virtual planning and evaluation of liver
surgeries from pre-operative 3D imaging and intra-opera-
tive navigation support into the world of HDR-BT. The goal
is to investigate the feasibility and accuracy of a navigation
support for the placement of brachytherapy needles for liver
HDR-BT in a phantom, simulating liver metastases with
copper wires. In a second step, we evaluate how to trans-
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Fig. 1 Markers for needle (a) and patient (b) tracking
late the yielded accuracy results from the phantom study
into a clinical setting, along with the clinical exploration of
such an approach based on HDR-BT plans.
Materials andmethods
Experiments carried out in this work are twofold and consist
of the investigation (1) of the feasibility of using a pre-
viously available stereotactic image-guidance system for
CT-based interventions for the placement of HDR-BT ap-
plicators in a realistic phantom in which liver metastases
were mimicked using copper wires. We have measured the
accuracy of navigated needle placement and compared it
with the accuracy of historical experience of free-hand nee-
dle placement in a phantom and translated these results
into a clinical setting. Subsequently, (2) we have retrospec-
tively created HDR-BT plans of patients with colorectal
liver metastasis by taking the measurement results from the
phantom experiment into account to explore what impact
a potential inaccuracy of the needle placement with a nav-
igation system would have on HDR-BT dosimetry.
Feasibility of image-guidedHDR-BT placement
System overview
A previously available navigation system for percutaneous
interventional procedures (CAS-One IR, CAScination AG,
Bern, Switzerland; [17]) was adapted to investigate the
experimental feasibility of brachytherapy needle placement
during intra-operative HDR-BT. This system combines
planning of the needle trajectories in CT data and the
subsequent placement of these needles (i.e., ablation ap-
plicators) under real-time guidance. It tracks both the
patient and needle placement process through an optical
position measurement system (NDI Vicra, Northern Dig-
ital, Canada). Marker shields with retro-reflective passive
markers can be adapted and attached to a variety of in-
terventional tools (Fig. 1a). The system provides tracking
of the patient’s respiratory motion through retro-reflective
markers, which are attached to the patient’s skin prior to
the acquisition of a planning CT (Fig. 1b). Their positions
are then automatically detected in the CT slices [18]. Per
tracking cycle (20Hz), the optically detected marker posi-
tions are co-registered to the image data using a rigid point-
based registration algorithm. The resulting fiducial regis-
tration error (FRE) is computed and serves as a correlate
of the available deformation of the patient’s abdomen due
to respiratory motion.
The system allows for image-based identification of the
target and organs at risk as well as the planning of the
planned needle trajectories (Fig. 2). Subsequently, the nee-
dle placement is carried out using the system’s integrated
guiding functionality consisting of an abstract cross-hair
view as well as an image-based guiding viewer (Fig. 3). The
user initially aligns the needle tip relative the prospective
entry, and adjusts the needle’s correct longitudinal align-
ment. Once alignment and orientation are according to the
plan, the needle can be advanced towards the target. The
system was adapted to enable the experiments described in
this work.
Image-guided placement of HDR-BT applicators
The feasibility of the workflow and the accuracy of the sys-
tem were evaluated by performing three punctures on a re-
alistic phantom. This phantom was made of a gelatin-filled
plastic bag placed inside a 1:1 scale plastic torso (Fig. 1b).
Liver metastases within the phantom were mimicked using
copper wires. Five copper wires of a diameter of 1.6mm
were inserted inside the gelatin-filled plastic bag and served
as targets. Six retro-reflective markers were glued to the
phantom surface for deformation tracking and a pre-inter-
ventional CT scan of the phantom was acquired. The place-
ment experiment was carried out as follows:
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Fig. 2 When the needle is far
away from the planned entry, the
system displays a reconstruction
of the treatment plan with the
whole organ, an isodose volume
(in red), and the planned needle
trajectories (in dark blue, purple,
grey, yellow and light blue). The
yellow trajectory is currently
activated
Fig. 3 When the needle is
close to the planned entry, the
system displays a cross-hair
viewer (a), where the needle
tip is represented by a cross
and the needle shaft by a circle.
A depth bar guides the user
towards the target. Displayed
in b is a resliced CT, showing
the current path of the needle.
The curve at the bottom of the
screen displays the amplitude of
patient deformation
1. In the first step of the evaluation, a planning target vol-
ume (PTV) containing one of the copper wires was man-
ually delineated in the CT data.
2. A treatment plan ensuring a PTV coverage of 97% with
three needles was designed.
3. Up to three punctures were performed along the planned
trajectories (Fig. 4).
4. A post-interventional control CT was acquired after nee-
dle insertion in which the position of the inserted needles
was reconstructed and the actual dose to the PTV re-cal-
culated.
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Fig. 4 Experimental setup with the navigation system (1), the phan-
tom (2), and the remote afterloader (3), HDR high-dose rate
Fig. 5 Example of the three-dimensional workup of an individual
dataset. The image shows the hepatic veins (blue), the portal vein
(blue-green) and the vessel of interest (orange). The metastases are
seen a brown masses, distributed in both liver lobes.
Evaluation of the image guidance system
In order to evaluate the feasibility of the guidance approach,
the accuracy of the system, defined as target positioning
error (TPE), was assessed. It was computed for each needle
as the distance between the planned and the achieved needle
tip position. TPE was separated into a lateral component
(along the needle trajectory) and the angular component.
The overall accuracy of the approach was also investigated
by computing the dose delivered to the PTV and comparing
it to the intended dose.
Retrospective suitability assessment for HDR-BT
Retrospectively, available anonymized multiphasic, con-
trast-enhanced CT scans of the liver image data and cor-
responding 3D workup (MeVis Medical Solutions AG,
Germany; Fig. 5) of 5 patients with colorectal liver metas-
tases previously treated with a combination of surgical liver
resection and/or ablation (treated in our hospital between
06/2011 and 06/2012) were selected for use in this analysis
(see Table 1 for a description of the selected datasets).
More specifically, anonymized image data of those patients
who met the following criteria were identified: eligibility
for surgery, hepatic tumor load< 40% of total liver volume
or less than 6 liver metastases, ≥1 lesion located next to
a critical structure. Exclusion criteria for this study were
>6 metastases and presence of primary liver tumors.
HDR-BT treatment planning
For the selected patients, HDR-BT plans were generated
within the treatment planning system Masterplan v4.1 (Nu-
cletron, Elekta AB, Stockholm, Sweden). Contouring and
3D dose optimization were performed on patients’ pre-in-
terventional CT datasets with slice thicknesses of 1mm. For
each patient, gross target volumes (GTV) were defined and
manually contoured. From each GTV, a clinical target vol-
ume (CTV) was created by adding a 0.5mm margin. Since
the setup errors in brachytherapy can be assumed to be
negligible, CTV corresponds to PTV. In general, for PTVs
up to a diameter of 2cm, one applicator was used, while
for PTVs larger than 2cm, two to three applicators were
employed to improve conformity of the dose distribution.
Dwell positions and weights of each applicator were modi-
fied until dose–volume constraints were optimally achieved.
Prescription dose (PD) of the CT plans was 20Gy, with the
dosimetric goal to cover at least 90% of the PTV with the
PD (V100% PTV≥ 90%). For the resulting treatment plans,
dose–volume histogram (DVH) parameters for PTV and
OARs were evaluated.
Results
Feasibility of image guidance
The achieved TPE with the navigation system was 4.2mm
± 1.2mm, with an average lateral error of 0.5mm± 0.1mm
and an average angular error of 2.6°± 0.4°. In the pre-in-
terventional planning, 97% of the PTV received 100% of
the dose (V100%). After the insertion of three brachytherapy
needles with the navigation system, the post-interventional
plan shows that V100% decreased to 87% (Fig. 6).
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Table 1 Description of the
selected study group ID No. of lesions Volume (ml) Location of Lesions
Patient 1 4 17 Segments IV, V
Patient 2 5 52 Segments III, IV, VII, VIII
Patient 3 1 24 Segment VIII
Patient 4 4 3 Segments V, VI, VII, VIII
Patient 5 3 12 Segments III, IV, VII
Fig. 6 Dose–volume histograms of planned and achieved dose distri-
butions
Suitability of treatment planning
Over the five selected patient plans, 13 PTVs ranging be-
tween 2.2cm3 and 65.3cm3 were contoured. The average
coverage (V100%) of the 13 PTVs was 94.2± 2.9%. For
a PD of 20Gy per fraction, an average median dose of
2.8± 1.1Gy to the normal liver (Liver-PTV) was calcu-
lated. For the same PD and a typical source strength of
4 x 104 cGy x cm2/h, the total treatment times last between
8 and 32min.
Over the five patient plans, the conformal index (COIN)
according to [19] was 0.55± 0.03.
Discussion and conclusion
General surgical stereotactic systems have been known
since the early 1990s and enable surgeons to virtually plan
and evaluate surgical strategies prior to the actual surgery
using the available imaging data from CT or MR imaging.
Immobile skeletal structures such as the rigid neurocranium
provided the optimal setting for precise image guidance.
Therefore, initial experiences with computer-assisted and
image-guided surgery were mainly gained from rigid struc-
tures and applied in neurosurgery, complex craniofacial
surgery, and orthopedic surgery [36]. In contrast, the liver
parenchyma is exposed to constant breathing motion and
organ deformation. Only more recently for HPB surgery
have first image guidance systems taken the complexity of
the liver itself into account to a sufficient level to permit
their application in daily clinical practice [38, 39]. Nev-
ertheless, bridging the gap between virtual pre-operative
intervention planning and intra-operative navigation sup-
port for the real-time reproduction of the virtually planned
intervention remains a challenge. Deformations of the liver
of up to 20mm have been detected when compared to
a pre-operatively acquired 3D tomographic image [40].
Thus, the fundamental challenge in image guidance in liver
interventions is a correct and real-time referencing of the
pre-operatively acquired image data (3D- and 4D-/contrast-
enhanced/CT or MRI) with the actual intra-operative sit-
uation. Such a navigational support of an optically based
instrument guidance system is already in use in our hospi-
tal for open liver surgery [15] and MWA [16]. Currently,
such image-guided navigation systems are not used for the
placement of applicators for liver HDR-BT. In the present
study, we demonstrate the potential use of this available
image-guidance technology for interventional procedures
with specific adaptions to accommodate the placement of
HDR-BT applicators.
Initial studies of intra-operative liver brachytherapy first
described the technique in the 1980s [20–22]. At that time,
applicator placement was guided either by manual palpa-
tion or sonographic monitoring [22]. In such a situation,
neither adequate coverage of the target volume nor ex-
act sparing of adjacent critical structures could be guar-
anteed. A decade ago, image-guided brachytherapy of liver
tumors was introduced [11], in which an iridium-192 source
is temporarily inserted into the tumor through catheters
placed under CT image guidance [11, 23–25]. In the present
study, we demonstrate an effective geometric accuracy of
4.2mm± 1.2mm for the placement of the HDR-BT appli-
cators using such an available image-guidance technology
for interventional procedures, with a potential degrading of
V100% in the PTV from 97 to 87% (Fig. 7). In a subsequent
study at our department [26], we analyzed the dosimetric
impact of geometric uncertainties (i.e., tumor size, shape,
number of lesions, needle length and position, number of
needles as well as OAR and target volume coverage) in nav-
igated HDR-BT for liver tumors by applying different shifts
(5mm and 1cm) to a known dose distribution. It was
found that for small PTVs below 2cm, the deviations for
dose coverage and dose conformity can be up to 50%. The
effect depends on the number as well as on the placement
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and arrangement of needles and decreases with increasing
tumor size. For larger PTVs, the reduction in dose cover-
age for a 5mm shift is between 5 and 10%. It was further
concluded that where no other treatment modality is avail-
able, such a navigation-guidance method for intra-operative
HDR-BT seems to be promising. However, specific inclu-
sion/exclusion criteria for patient selection for navigated
intra-operative HDR-BT remain unclear at this stage.
In clinical practice, several possibilities exist to over-
come these uncertainties. Using more than one applicator
for a liver brachytherapy plan enables better coverage of
complex-shaped tumor volumes, as well as better protection
of the healthy surrounding tissue with its rapid dose fall-
off outside the target lesion. It also increases the robustness
of the plan. Additionally, the non-optimal placement of the
brachytherapy needle can be compensated by a correspond-
ing adjustment of the dwell time of the source within the
target volume. With these various adjustable elements for
planning, the minimum target dose at the tumor border can
be achieved with no compromise in target coverage. Since
the goal in liver brachytherapy is to cause necrosis in the
tumor, dose heterogeneity within the target volume is of no
concern and no maximum dose limit exists [27, 32].
Fig. 7 Example of planned (a) and achieved (b) dose distributions in a patient with a PTV volume of 6.6ml (median volume over the analyzed
patient collective). The achieved dose distribution was simulated applying a TPE of 4.2mm ± 1.2mm. c Dose–volume histograms of planned and
achieved dose distributions
The assessment of the present datasets indicates the fea-
sibility of navigated intra-operative HDR-BT. The method
is potentially feasible for all these patients with either a hep-
atic tumor load below 40% of the total liver volume or less
than six liver metastases larger than 4cm. For the selected
datasets, acceptable doses to the normal liver as well as
acceptable treatment times have been observed. The risk
of harming blood vessels by placing applicators in liver
brachytherapy is potentially mitigated through the use of
the described guidance method by reducing the need for re-
placement due to inaccuracy.
In clinical practice we often face complex settings in
patients with CRC hepatic metastases, such as multiple,
synchronous, bi-lobar, and large hepatic lesions that are
located near critical structures or blood vessels. Combining
this navigation-guided intraoperative HDR-BT with surgery
and MWA also opens new opportunities for a combined
treatment approach at the same time. Such a computer-
navigated system may facilitate the application of HDR-
BT for the placement of BT applicators and planning of
liver HDR-BT also in situations where HDR-BT was not
initially planned to be part of the intervention.
With regards to the dose prescription, in the present study
we prescribed 20Gy to at least 90% of the PTV. Previ-
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ous studies of intraoperative brachytherapy for liver can-
cers proposed that tumor-enclosing isodoses of 15 to 30Gy
should be used [20–22, 28]. In a prospective randomized
trial of 73 patients with 199 colorectal liver metastases,
Ricke et al. [29] evaluated the minimal dose levels enclos-
ing the CTV of 15, 20, and 25Gy. They found a dose
dependency for local control if the minimum dose in the
target exceeded 20.4Gy. In a multivariate analysis, lesion
size (range of tumors 1–13.5cm) had no impact on local
control. However, in tumors larger than 8cm, excessive ir-
radiation time and unpredictable risks aggravated the deliv-
ery of >20Gy in a single fraction. Nevertheless, these data
show that lesions up to a diameter of 8cm can be safely
treated with a single fraction of 20Gy applied by HDR-BT.
There are several limitations to this feasibility study.
First, any conclusions revealed here are hypothesis-generat-
ing and, as such, will need to be validated within a prospec-
tive study. Several open questions for intraoperative nav-
igation-guided HDR-BT remain: it is unclear how many
applicators need to be placed for lesions> 8cm and what
conformity should be achieved, especially in bigger lesions.
With only one applicator, dose conformity might be too low.
More applicators might provide a better conformity of dose
distribution. We suggest the number of applicators should
depend on the size of the lesion. Also, dose constraints
for liver HDR-BT are unclear. In their studies, Ricke et al.
[28] used a maximum dose exposure of 5Gy to maximally
two thirds of the liver volume as a liver constraint. In their
2005 published study [25] on dose–response relationship
for small volumes of liver parenchyma after single-fraction
HDR irradiation, they used, after brachytherapy, a hepa-
tocyte-specific contrast agent media uptake (Gd-BOPTA)
for liver MRI as a surrogate for liver function. They found
that the lowest threshold dose to impair hepatocyte func-
tion was 9.9Gy (standard deviation 2.3Gy) at 6 weeks
after irradiation with repair ongoing until 3 months. Af-
ter single-fraction stereotactic body radiotherapy (SBRT)
to liver malignancies, Herfarth et al. [30] observed a focal
reaction after contrast CT at a dose minimum of 13.7Gy
(range 8.9–19.2), which is consistent with the experience in
brachytherapy. In the current study, we have used the dose
constraints for stereotactic body radiation therapy (SBRT)
according to Grimm et al. [31], with which technique also
high doses of single fractions can be applied [35].
Since the technology of this system was initially de-
veloped for intra-operative support of liver resection and
MWA, we have used this clinical setting to evaluate the
potential benefit of the use of such a navigation system
for liver BT. However, the use of this stereotactic naviga-
tion system opens also new opportunities for the placement
of HDR-BT applicators within the liver by percutaneous
CT guidance in patients with large, centrally localized liver
metastases where no resection or MWA intervention is in-
dicated. It may provide support in pre-interventional treat-
ment planning (i.e., needle path, multi-applicator configu-
ration) and applicator placement (i.e., angle and depth guid-
ance).
In conclusion, we provide evidence for the technical fea-
sibility of navigation-guided intra-operative HDR-BT and
propose a set of inclusion criteria for clinical testing.
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